Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery

What Was Tested

In this not phased trial, researchers set out to test NAD+.

In patients in intensive care units, it is the second most common type of AKI after AKI secondary to sepsis.

There is currently no specific treatment for AKI.

It had two arms (groups): Riboside (RN) arm (experimental) and Placebo arm (placebo comparator).

The registry classes the interventions as dietary supplement and other.

More on the Plan

As far as the researchers know, there is no study that evaluates the impact of the administration of nicotinamide riboside on renal function in patients undergoing cardiac surgery.

Nicotinamide adenine dinucleotide (NAD+) is a cellular factor related to metabolism and longevity.

NAD+ is a required cofactor of SIRT1, a nuclear deacetylase that modulates chromatin structure, gene expression, prolongs lifespan in organisms, and ameliorates age-related diseases.

Likewise, mice deficient in SIRT1 are more susceptible to AKI and when there is overexpression of SIRT1 they are protected from AKI.

Who Took Part

The registry lists 100 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Heart valve replacement surgery. Sign of informed consent.

The full record lists 2 inclusion and 7 exclusion criteria; among the exclusions: allergy to any of the components; platelet count less than 100,000; weight less than 50kg or over 100kg.

How the Study Was Run

It was run as a randomized, parallel-group and triple-blind study.

Because people in this NAD+ study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received NAD+.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2024-07-24 with completion listed for 2025-07-31.

It ran at 1 site in Mexico.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Impact of nicotinamide riboside (NR) on kidney function in patients undergoing cardiac surgery (time frame: 2 years).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 100 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.